[go: up one dir, main page]

PE20190761A1 - Inhibidores de procesos metabolicos celulares - Google Patents

Inhibidores de procesos metabolicos celulares

Info

Publication number
PE20190761A1
PE20190761A1 PE2019000437A PE2019000437A PE20190761A1 PE 20190761 A1 PE20190761 A1 PE 20190761A1 PE 2019000437 A PE2019000437 A PE 2019000437A PE 2019000437 A PE2019000437 A PE 2019000437A PE 20190761 A1 PE20190761 A1 PE 20190761A1
Authority
PE
Peru
Prior art keywords
metabolic process
cellular metabolic
inhibitors
alkyl
refers
Prior art date
Application number
PE2019000437A
Other languages
English (en)
Inventor
Jeremy M Travins
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59846695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20190761(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/CN2016/097524 external-priority patent/WO2018039972A1/en
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of PE20190761A1 publication Critical patent/PE20190761A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/141Esters of phosphorous acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a un compuesto de formula IA o una de sus sales farmaceuticamente aceptables, en donde: RA es H, alquilo C1-C6, entre otros; RB es H, alquenilo C2-C6 y alquilo C1-C6; RC, RD y RE son por separado carbociclo C3-C14, arilo C6-C14 y heterociclo de 3 a 14 miembros (1 a 4 de estos miembros son N, O o S). Tambien se refiere a una composicion farmaceutica y a metodos de preparacion. Dichos compuestos son inhibidores de la enzima MAT2A (metionina adenosiltransferasa 2A) y son utiles en el tratamiento de cancer
PE2019000437A 2016-08-31 2017-08-30 Inhibidores de procesos metabolicos celulares PE20190761A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2016/097524 WO2018039972A1 (en) 2016-08-31 2016-08-31 Inhibitors of cellular metabolic processes
US201762548738P 2017-08-22 2017-08-22
PCT/US2017/049439 WO2018045071A1 (en) 2016-08-31 2017-08-30 Inhibitors of cellular metabolic processes

Publications (1)

Publication Number Publication Date
PE20190761A1 true PE20190761A1 (es) 2019-06-05

Family

ID=59846695

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000437A PE20190761A1 (es) 2016-08-31 2017-08-30 Inhibidores de procesos metabolicos celulares

Country Status (19)

Country Link
US (4) US10329298B2 (es)
EP (1) EP3507290A1 (es)
JP (2) JP6832430B2 (es)
KR (1) KR102411150B1 (es)
CN (1) CN109890822B (es)
AU (2) AU2017319500C1 (es)
CA (1) CA3034705C (es)
CL (1) CL2019000511A1 (es)
CO (1) CO2019002237A2 (es)
CR (1) CR20190157A (es)
IL (1) IL265115B (es)
MA (1) MA46092A (es)
MX (1) MX390277B (es)
NI (1) NI201900019A (es)
PE (1) PE20190761A1 (es)
SG (1) SG11201901747VA (es)
TW (1) TWI762505B (es)
UA (1) UA125852C2 (es)
WO (1) WO2018045071A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20190761A1 (es) 2016-08-31 2019-06-05 Agios Pharmaceuticals Inc Inhibidores de procesos metabolicos celulares
WO2019040499A2 (en) * 2017-08-21 2019-02-28 Navigen, Inc. ARF6 INHIBITORS AND ASSOCIATED METHODS
BR112020003676A2 (pt) 2017-09-15 2020-09-01 Aduro Biotech, Inc. compostos de pirazolopirimidinona e usos dos mesmos
AU2019243289B2 (en) 2018-03-30 2023-01-12 Les Laboratoires Servier Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
CN113166078B (zh) * 2018-12-10 2024-11-19 伊迪亚生物科学有限公司 2-氧代喹唑啉衍生物作为甲硫氨酸腺苷转移酶2a抑制剂
CR20210409A (es) * 2018-12-27 2022-01-24 Les Laboratoires Servier Sas Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
SI3902803T1 (sl) 2018-12-27 2023-06-30 Les Laboratoires Servier Aza-heterobiciklični inhibitorji mat2a in postopki uporabe za zdravljenje raka
WO2020167952A1 (en) * 2019-02-12 2020-08-20 Mirati Therapeutics, Inc. Mat2a inhibitors
TW202045155A (zh) 2019-02-13 2020-12-16 美商阿吉歐斯製藥公司 用於治療癌症之組合療法
WO2021023609A1 (en) 2019-08-02 2021-02-11 Glaxosmithkline Intellectual Property Development Limited Combination of a type i protein arginine methyltransferase (type i prmt) inhibitor and a methionine adenosyltransferase ii alpha (mat2a) inhibitor
BR112022010054A2 (pt) 2019-11-25 2022-08-16 Amgen Inc Compostos heterocíclicos como inibidores de delta-5 dessaturase e métodos de uso
WO2021139775A1 (zh) * 2020-01-10 2021-07-15 江苏先声药业有限公司 吡啶酮化合物及应用
WO2021158792A1 (en) * 2020-02-04 2021-08-12 Agios Pharmaceuticals, Inc. Methods of treating autoimmune or inflammatory diseases or disorders
CN116406271B (zh) * 2020-07-14 2024-09-24 南京再明医药有限公司 双环类化合物
CN113999232B (zh) * 2020-07-28 2025-01-07 南京正大天晴制药有限公司 Mat2a抑制剂
IL300147A (en) * 2020-07-31 2023-03-01 Tango Therapeutics Inc History Piperidin-1-yl-N-pyridin-3-yl-2-oxaacetamide is useful for the treatment of MTAP-deficient and/or MTA-accumulating cancer
AR123227A1 (es) * 2020-08-12 2022-11-09 Servier Pharmaceuticals Llc Terapias combinadas para su uso en el tratamiento del cáncer
TW202227446A (zh) 2020-08-12 2022-07-16 美商施維雅製藥有限公司 有機化合物之固態形式
WO2022063128A1 (zh) * 2020-09-24 2022-03-31 上海凌达生物医药有限公司 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用
CN116782903A (zh) * 2020-10-15 2023-09-19 南京再明医药有限公司 取代的吡啶酮化合物及应用
TW202237610A (zh) * 2020-11-25 2022-10-01 法商施維雅藥廠 新穎有機化合物
WO2022143864A1 (zh) 2020-12-31 2022-07-07 江苏先声药业有限公司 三环类化合物及用途
US20240075017A1 (en) 2021-03-08 2024-03-07 Technische Universität München Treatment of coronavirus infections using sam cycle inhibitors
EP4313988A4 (en) * 2021-03-26 2025-03-19 Orphagen Pharmaceuticals, Inc. PYRAZOLOPYRIMIDINONE COMPOUNDS
AR125304A1 (es) * 2021-04-08 2023-07-05 Genentech Inc Compuestos de oxazepina acíclicos y usos de los mismos
JP2024116429A (ja) * 2021-07-06 2024-08-28 国立研究開発法人産業技術総合研究所 組織の老化を予防または治療するための組成物
CN115716831B (zh) * 2021-08-25 2024-07-02 中国科学院分子细胞科学卓越创新中心 一种mat2a抑制剂及其在抗病毒中的应用
WO2023083210A1 (zh) * 2021-11-09 2023-05-19 上海海雁医药科技有限公司 取代的萘啶酮衍生物、其药物组合物及应用
WO2023086934A1 (en) * 2021-11-12 2023-05-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a taxane
CN116283994B (zh) * 2021-12-20 2025-01-07 艾立康药业股份有限公司 作为mat2a抑制剂的杂环化合物
WO2023116696A1 (zh) 2021-12-21 2023-06-29 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
GB202204913D0 (en) 2022-04-04 2022-05-18 Cambridge Entpr Ltd antiviral therapy
CN116987084A (zh) * 2022-04-26 2023-11-03 上海交通大学 吡唑并嘧啶类化合物及其盐、溶剂合物、组合物和应用
PE20251525A1 (es) 2022-10-13 2025-06-05 Hanmi Pharmaceutical Co Ltd Compuesto derivado triciclico novedoso y usos del mismo descripcion
EP4619104A1 (en) * 2022-11-16 2025-09-24 Novartis AG Bicyclic heterocycles and their use as wrn inhibitors
CN116425751B (zh) * 2022-12-19 2024-01-23 艾立康药业股份有限公司 作为mat2a抑制剂的多环类化合物
CN116425721B (zh) * 2022-12-19 2024-02-02 艾立康药业股份有限公司 作为mat2a抑制剂的双环类化合物
WO2024153244A1 (zh) * 2023-01-20 2024-07-25 南京再明医药有限公司 含氮类化合物
WO2024230828A1 (en) * 2023-05-11 2024-11-14 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
WO2025064750A1 (en) 2023-09-20 2025-03-27 Ideaya Biosciences, Inc. Combination therapy with a parg inhibitor
WO2025072544A1 (en) 2023-09-27 2025-04-03 Ideaya Biosciences, Inc. Sulfonamino indazole compounds as inhibitors of parg
WO2025166229A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic amidino compounds as prmt5 inhibitors
WO2025166257A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166260A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted tricyclic guanidino compounds as prmt5 inhibitors
WO2025166274A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic guanidino compounds as prmt5 inhibitors
WO2025166215A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Triheterocyclic guanidino compounds as prmt5 inhibitors

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714880A1 (de) 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
EP0218385B2 (en) 1985-09-17 1997-05-14 Konica Corporation Thermally developable light-sensitive material
US4950585A (en) 1987-08-18 1990-08-21 Konica Corporation Coupler for photographic use
JPH01271751A (ja) 1988-04-23 1989-10-30 Konica Corp 新規な写真用カプラーを含有するハロゲン化銀カラー写真感光材料
JPH03172839A (ja) 1989-12-01 1991-07-26 Konica Corp 新規な写真用カプラー
JPH04133055A (ja) 1990-09-25 1992-05-07 Konica Corp 色再現性の改良されたハロゲン化銀カラー写真感光材料
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
JPH05125079A (ja) 1991-11-05 1993-05-21 Otsuka Pharmaceut Factory Inc ピラゾロ[1,5−aピリミジン誘導体
JPH07253630A (ja) 1994-03-15 1995-10-03 Konica Corp 直接ポジハロゲン化銀カラー写真感光材料及び直接ポジカラー画像形成方法
US5902773A (en) 1995-05-09 1999-05-11 Basf Aktiengesellschaft Pyrazolo-(1,5a)-pyrimidines, process for preparing the same and their use
JPH08325248A (ja) 1995-05-26 1996-12-10 Chugoku Kayaku Kk テトラゾール類の新規な合成試薬及びそれを用いたテトラゾール類の製造方法
JPH095630A (ja) 1995-06-15 1997-01-10 Nikon Corp 光走査方法
FR2746309B1 (fr) 1996-03-22 1998-04-17 Oreal Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
FR2750048B1 (fr) 1996-06-21 1998-08-14 Oreal Compositions de teinture des fibres keratiniques contenant des derives pyrazolo-(1, 5-a)-pyrimidine, procede de teinture, nouveaux derives pyrazolo-(1, 5-a)-pyrimidine et leur procede de preparation
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6124289A (en) 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US5817663A (en) 1996-10-07 1998-10-06 American Cyanamid Company Pentafluorophenylazolopyrimidines
AU6797298A (en) 1997-04-15 1998-11-11 Genentech Inc. Halo-alkoxycarbonyl prodrugs
FR2767685B1 (fr) 1997-09-01 2004-12-17 Oreal Composition pour la teinture d'oxydation des fibres keratiniques comprenant du 2-chloro 6-methyl 3-aminophenol et une base d'oxydation, et procede de teinture
FR2779948B1 (fr) 1998-06-19 2004-04-23 Oreal Composition tinctoriale contenant du 1,8-bis- (2,5-diaminophenoxy)-3,5-dioxaoctane, une base d'oxydation additionnelle et un coupleur, et procedes de teinture
FR2779951B1 (fr) 1998-06-19 2004-05-21 Oreal Composition tinctoriale contenant une pyrazolo-[1,5-a]- pyrimidine a titre de base d'oxydation et un coupleur naphtalenique, et procedes de teinture
US20020062529A1 (en) 1998-06-19 2002-05-30 L'oreal S.A. Dye composition containing 1,8-bis(2,5-diaminophenoxy)-3,6-dioxaoctane, an additional oxidation base and a coupler, and dyeing processes
FR2779950B1 (fr) 1998-06-19 2004-05-21 Oreal Composition de teinture d'oxydation des fibres keratiniques et procede de teinture mettant en oeuvre cette composition
FR2779952B1 (fr) 1998-06-19 2000-08-04 Oreal Composition tinctoriale contenant une pyrazolo-[1,5-a]- pyrimidine a titre de base d'oxydation et un coupleur pyridinique, et procedes de teinture
FR2779949B1 (fr) 1998-06-19 2004-05-21 Oreal Composition de teinture d'oxydation des fibres keratiniques et procede de teinture mettant en oeuvre cette composition
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
JP2000089418A (ja) 1998-09-08 2000-03-31 Konica Corp 画像記録材料、直接ポジ型ハロゲン化銀写真感光材料及び画像形成方法
US6277857B1 (en) 1998-09-25 2001-08-21 American Cyanamid Company Fungicidal 7-oxy-and 7-thio-substituted-triazolopyrimidines
FR2784380B1 (fr) 1998-09-25 2002-09-06 American Cyanamid Co Triazolopyrimidines 7-oxy- et 7-thio-substituees fongicides
US6531477B1 (en) 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
FR2785183B1 (fr) 1998-11-04 2002-04-05 Oreal COMPOSITION TINCTORIALE CONTENANT UN COLORANT DIRECT CATIONIQUE ET UNE PYRAZOLO-[1,5-a]- PYRIMIDINE A TITRE DE BASE D'OXYDATION, ET PROCEDES DE TEINTURE
JP2000153671A (ja) 1998-11-20 2000-06-06 Fuji Photo Film Co Ltd 感熱記録材料
FR2791562B1 (fr) 1999-03-29 2004-03-05 Oreal Composition tinctoriale contenant une pyrazolo-[1,5-a]- pyrimidine et une polyaminopyrimidine monocyclique a titre de bases d'oxydation et un coupleur, et procedes de teinture
FR2791563A1 (fr) 1999-03-29 2000-10-06 Oreal Composition de teinture d'oxydation des fibres keratiniques et procede de teinture mettant en oeuvre cette composition
JP4193285B2 (ja) 1999-06-04 2008-12-10 コニカミノルタホールディングス株式会社 カラートナー
US6420057B1 (en) 1999-07-05 2002-07-16 Konica Corporation Organic electroluminescent element
JP2003510326A (ja) 1999-09-30 2003-03-18 ニューロジェン・コーポレーション アミノ置換ピラゾロ[1,5−a]−1,5−ピリミジン類及びピラゾロ[1,5−a]−1,3,5−トリアジン類
EA200200422A1 (ru) 1999-09-30 2002-10-31 Ньюроджен Корпорейшн НЕКОТОРЫЕ АЛКИЛЕНДИАМИНОЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]-1,5-ПИРИМИДИНЫ И ПИРАЗОЛО[1,5-а]-1,3,5-ТРИАЗИНЫ
US20020041880A1 (en) 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
JP2002326462A (ja) 2001-04-27 2002-11-12 Fuji Photo Film Co Ltd 感熱記録材料
FR2831055B1 (fr) 2001-10-24 2004-05-28 Oreal Composition tinctoriale comprenant au moins une base heterocyclique et le 1-n-(b-hydroxyethyl) 4-hydroxy indole a titre de coupleur ; procedes de teinture
ES2337775T3 (es) 2001-11-17 2010-04-29 HENKEL AG & CO. KGAA Agentes colorantes por oxidacion a base de componentes de agentes reveladores de dos nucleos.
GB0130418D0 (en) 2001-12-20 2002-02-06 Eastman Kodak Co Photographic elements containing a deaggregating compound and dye forming coupler
GB0130416D0 (en) 2001-12-20 2002-02-06 Eastman Kodak Co Photographic elements containing a de-aggregating compound dye-forming coupler and stabilizer
JP2003301009A (ja) 2002-04-10 2003-10-21 Konica Minolta Holdings Inc 光重合開始剤、ラジカル発生方法、光重合組成物、平版印刷版作成用感光材料及び平版印刷版の作成方法
JP4602076B2 (ja) 2002-06-04 2010-12-22 ネオジェネシス ファーマシューティカルズ インコーポレイテッド 抗ウイルス剤としてのピラゾロ[1,5a]ピリミジン化合物
PL382706A1 (pl) 2002-08-26 2007-11-26 Takeda Pharmaceutical Company Limited Związek modulujący receptor wapnia i jego zastosowanie
AU2003299651A1 (en) 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
AU2003303094A1 (en) * 2002-12-30 2004-08-13 Exelixis, Inc. MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
EP1599482A4 (en) 2003-02-28 2008-10-01 Teijin Pharma Ltd PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
ATE418555T1 (de) 2003-04-09 2009-01-15 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
JP4795634B2 (ja) 2003-10-31 2011-10-19 出光興産株式会社 有機薄膜トランジスタ
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
WO2005103052A1 (en) 2004-04-21 2005-11-03 Pfizer Products Inc. Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof
GB0516378D0 (en) 2005-08-09 2005-09-14 Eirx Therapeutics Ltd Compound
CA2620740A1 (en) 2005-09-01 2007-03-08 Astellas Pharma Inc. Pyridazinone derivatives used for the treatment of pain
WO2007071688A1 (en) 2005-12-22 2007-06-28 L'oréal Composition for dyeing keratin fibres with a tetraazapentamethine cationic direct dye, a particular oxidation base and a coupler
WO2007102531A1 (ja) 2006-03-08 2007-09-13 Takeda Pharmaceutical Company Limited 併用薬
MX2008011853A (es) 2006-03-17 2008-09-29 Wyeth Corp Derivados de pirazolo[1,5-a]pirimidina y sus metodos de uso.
EP2233472B1 (en) 2006-03-28 2014-01-15 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
WO2007118844A1 (de) 2006-04-13 2007-10-25 Basf Se Substituierte pyrazolopyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen sowie sie enthaltende mittel
US20080021217A1 (en) 2006-07-20 2008-01-24 Allen Borchardt Heterocyclic inhibitors of rho kinase
WO2008019309A1 (en) 2006-08-04 2008-02-14 Metabasis Therapeutics, Inc. Novel inhibitors of fructose 1,6-bisphosphatase
WO2008046856A2 (de) 2006-10-18 2008-04-24 Basf Se Fungizide zusammensetzungen
WO2008063671A2 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
JP2010510291A (ja) 2006-11-23 2010-04-02 ノバルティス アーゲー CXCR2アンタゴニストとしての5−スルファニルメチル−ピラゾロ[1,5−a]ピリミジン−7−オール
PT2114925E (pt) * 2006-12-22 2012-05-29 Einstein Coll Med Análogos de azetidina de inibidores de nucleosidase e fosforilase
JP5205794B2 (ja) 2007-04-26 2013-06-05 コニカミノルタホールディングス株式会社 光学フイルター用組成物、光学フィルター、ディスプレイ用前面フィルター及びスクアリリウム化合物
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
DE102007048447A1 (de) 2007-10-10 2009-04-16 Bayer Healthcare Ag Substituierte Dihydropyrazolthione und ihre Verwendung
DE102007049157A1 (de) 2007-10-13 2009-04-16 Bayer Healthcare Ag Substituierte Dihydrotriazolone und ihre Verwendung
US20100029657A1 (en) 2008-02-29 2010-02-04 Wyeth Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
CA2718403A1 (en) 2008-03-13 2009-09-17 The General Hospital Corporation Inhibitors of the bmp signaling pathway
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
GB0908957D0 (en) 2009-05-22 2009-07-01 Ucb Pharma Sa Therapeutic agents
CN101671336B (zh) * 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
MX2012006994A (es) 2009-12-18 2012-07-03 Mitsubishi Tanabe Pharma Corp Agente antiplaquetas novedoso.
US8877795B2 (en) 2010-05-07 2014-11-04 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
US8722563B2 (en) 2010-06-01 2014-05-13 Exxonmobil Research And Engineering Company Hydroprocessing catalysts and their production
SG10201505022WA (en) 2010-06-24 2015-07-30 Gilead Sciences Inc Pyrazolo [1, 5 -a] pyrimidines as antiviral agents
EP2402337A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2402344A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds
EP2402345A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds
EP2402343A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazole-fused bicyclic compounds
PH12013500299B1 (en) 2010-08-20 2019-03-08 Hutchison Medipharma Ltd Pyrrolopyrimidine compounds and uses thereof
US20140038953A1 (en) 2011-01-21 2014-02-06 The General Hospital Corporation Compositions and methods for cardiovascular disease
EP2673250B1 (en) * 2011-01-28 2016-11-23 University of Kentucky Research Foundation Stilbene analogs and methods of treating cancer
WO2012149157A2 (en) * 2011-04-26 2012-11-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
WO2012154610A1 (en) 2011-05-06 2012-11-15 Intellikine, Llc Reactive pi3k kinase inhibitors and uses thereof
EP2768834B1 (en) 2011-10-20 2016-04-27 Glaxosmithkline LLC Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2014119752A1 (ja) 2013-01-31 2014-08-07 三井化学アグロ株式会社 縮合環ピリミジン化合物及びそれを含む有害生物防除剤
EP2970266B1 (en) 2013-03-15 2018-01-31 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
WO2015012328A1 (ja) 2013-07-24 2015-01-29 武田薬品工業株式会社 複素環化合物
WO2015035062A1 (en) 2013-09-05 2015-03-12 Genentech, Inc. Antiproliferative compounds
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
CN106103444B (zh) 2014-03-04 2019-03-12 先正达参股股份有限公司 杀微生物的杂二环衍生物
WO2015134770A1 (en) 2014-03-07 2015-09-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treating soft tissue via controlled drug release
FR3022454B1 (fr) 2014-06-20 2017-10-06 Oreal Procede de coloration des fibres keratiniques comprenant l'application d'un colorant auto-oxydable et d'une base d'oxydation (hetero)cyclique particuliere en l'absence d'oxydant
FR3022455B1 (fr) 2014-06-20 2017-09-01 Oreal Procede de coloration des fibres keratiniques comprenant l'application d'une base d'oxydation (hetero)cyclique particuliere en l'absence d'oxydant et en milieu riche en corps gras
US20170283440A1 (en) 2014-09-17 2017-10-05 Epizyme, Inc. Carm1 inhibitors and uses thereof
JP2018076234A (ja) 2015-03-16 2018-05-17 大正製薬株式会社 ピラゾロ[1,5−a]ピリミジン化合物
US9796722B1 (en) 2015-10-15 2017-10-24 Indiana University Research And Technology Corporation Hepatitis B viral assembly effectors
WO2017210678A1 (en) 2016-06-03 2017-12-07 An2H Discovery Limited Pyrazolopyrimidine derivatives and the compositions and methods of treatment regarding the same
WO2018039972A1 (en) 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
PE20190761A1 (es) 2016-08-31 2019-06-05 Agios Pharmaceuticals Inc Inhibidores de procesos metabolicos celulares
EP3449918A1 (en) 2017-09-01 2019-03-06 Technische Universität Dortmund Bmp-mimetics
BR112020003676A2 (pt) 2017-09-15 2020-09-01 Aduro Biotech, Inc. compostos de pirazolopirimidinona e usos dos mesmos

Also Published As

Publication number Publication date
MA46092A (fr) 2021-04-21
CN109890822B (zh) 2022-08-30
CN109890822A (zh) 2019-06-14
NI201900019A (es) 2019-04-29
JP2021073269A (ja) 2021-05-13
SG11201901747VA (en) 2019-03-28
US10329298B2 (en) 2019-06-25
AU2017319500B2 (en) 2020-08-27
BR112019003914A2 (pt) 2019-05-28
CL2019000511A1 (es) 2019-05-17
IL265115A (en) 2019-04-30
JP2019529529A (ja) 2019-10-17
AU2017319500C1 (en) 2022-10-20
NZ751515A (en) 2021-02-26
EP3507290A1 (en) 2019-07-10
US10800782B2 (en) 2020-10-13
MX2019002303A (es) 2019-07-15
KR20190046921A (ko) 2019-05-07
JP6832430B2 (ja) 2021-02-24
US11325914B1 (en) 2022-05-10
TW201811797A (zh) 2018-04-01
TWI762505B (zh) 2022-05-01
IL265115B (en) 2022-07-01
WO2018045071A1 (en) 2018-03-08
CO2019002237A2 (es) 2019-07-31
USRE49934E1 (en) 2024-04-23
AU2020277158A1 (en) 2020-12-24
US20180079753A1 (en) 2018-03-22
MX390277B (es) 2025-03-20
KR102411150B1 (ko) 2022-06-21
CR20190157A (es) 2019-08-13
UA125852C2 (uk) 2022-06-22
AU2017319500A1 (en) 2019-04-11
CA3034705C (en) 2021-08-03
US20190233424A1 (en) 2019-08-01
CA3034705A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
PE20190761A1 (es) Inhibidores de procesos metabolicos celulares
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
EA201992884A2 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
PE20142098A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
MX2020007023A (es) Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn).
PE20241296A1 (es) Inhibidores de fgfr y metodos de fabricacion y uso de los mismos
PE20160874A1 (es) Compuestos quimicos
PE20171307A1 (es) Compuestos de triazolopirimidina y usos de los mismos
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
MX390747B (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
EA201692480A1 (ru) Фармацевтическая композиция
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
PE20171337A1 (es) Inhibidores selectivos de bace1
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos
PE20190106A1 (es) Inhibidores del potenciador del homologo zeste 2
CY1109376T1 (el) Παραγωγα υδαντοϊνης χρησιμα ως αναστολεις μεταλλοπρωτεϊνασης
EA201692300A1 (ru) Производные карбоксамида
PE20171335A1 (es) Inhibidores de gingipaina de lisina
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201591649A1 (ru) Составы с органическими соединениями
CY1121060T1 (el) Παραγωγα [1,2,4] τριαζολο[1,5-α] πυριμιδινης ως αναστολεις πρωτεασωματος πρωτοζωων για τη θεραπεια παρασιτικων νοσηματων οπως η λεϊσμανιαση
EA202092558A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА ИНГИБИТОРА c-MET, ЕГО СОЛЕВАЯ ФОРМА И СПОСОБ ИХ ПОЛУЧЕНИЯ